The Mark Foundation Endeavor Award
Flagship collaborative cancer research grants funding multi-investigator, cross-disciplinary teams to solve urgent problems in oncology. Supports PI-led teams that integrate basic, translational, and clinical research, share datasets and resources, and translate multi-modal findings into patient-impacting advances—especially in high-need areas like upper GI, glioblastoma, triple-negative breast cancer, and pancreatic cancer.
Eligibility Criteria:
-
Institutional: One host submission per institution; a second allowed only for translational/clinical projects in upper GI, glioblastoma, triple-negative breast, or pancreatic cancer; nonprofit academic/research institutions worldwide.
-
Investigator: Independent faculty appointment; no citizenship/geography limits; PI may lead only one proposal.
-
Project: Basic/translational/clinical; overarching urgent question; integrated outputs; no overlapping funding.
-
Team: Inter-institutional collaborations encouraged; collaborators optional.
Funding Details:
-
USD 3,000,000 total over 3 years; indirect ≤10% of direct costs; budget apportioned to reflect actual work; award includes IP revenue-sharing terms.
Deadlines:
-
LOI due September 3, 2025 (11:59 p.m. ET).
-
Finalists: November 2025.
-
Full applications: January 2026.
-
Interviews: March 2026.
Where to Go for Further Information:
-
Submit via The Mark Foundation grants portal.
-
Questions: [email protected].
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023